Research

We focus on estimating the health, economic, and equity impact of vaccination programmes to support evidence-based decision-making on vaccination strategies in collaboration with partners and stakeholders at the global, regional, and national levels. Our vaccine value assessments are based on multiple criteria, including disease burden, health and economic impact of vaccination, benefit-risk assessment, equity, vaccine-preventable antimicrobial resistance, acceptability among stakeholders and the community, and broader socioeconomic benefits.

We conduct impact assessments of existing and new vaccines to inform vaccine policy across diverse contexts, geographies, and resource settings. Select projects are listed below. 

• OptiMAx

  • Integrated impact of nutritional supplementation and vaccination in children

• Human papillomavirus

  • HPV vaccine impact modelling in low- and middle-income countries (VIMC)

  • Stakeholder engagement and cost-effectiveness of HPV vaccination in China, Gabon, India, Japan, Kazakhstan, and Tanzania

• Chikungunya

  • Stakeholder engagement, chikungunya burden estimation, and vaccine impact modelling

• Nipah

  • Nipah virus transmission dynamics and vaccination strategies

• Typhoid

  • Burden of typhoid and associated antimicrobial  resistance to inform typhoid conjugate vaccine implementation in India

• Antimicrobial resistance

  • Bacterial antimicrobial resistance burden avertable by vaccination

Past projects

• Streptococcus A

  • Full value of vaccine assessment for potential Strep A vaccines (SAVAC)

• Rota virus

  • Potential health impact and cost-effectiveness of rotavirus vaccination in Afghanistan 

• COVID-19

  • Impact and benefit-risk of COVID-19 dosing interval strategies

• Childhood immunisation

  • Benefit-risk assessment of routine childhood immunisation during the COVID-19 pandemic

• Antimicrobial resistance

  • Development of vaccine and AMR monitoring using the One Health approach in Thailand and Laos PDR community

• Pneumococcus

  • Additional benefit of pneumococcal vaccine among elderly population in Japan and Thailand